Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. We have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Our additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease. Founded by ocular gene therapy pioneers Dr. Shannon Boye and Sanford Boye, Atsena has strong ties with the University of Florida. Our offices are located in Durham, NC, an environment rich in gene therapy expertise, and northern NJ.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $205M
Investors 5
| Date | Name | Website |
| 17.12.2020 | Sofinnova ... | sofinnova.... |
| 22.01.2021 | Lightstone... | lightstone... |
| 21.12.2020 | Abingworth... | abingworth... |
| - | Retinal De... | retinaldeg... |
| 22.05.2025 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.04.2025 | Series C | $150M | Sofinnova ... |
| 20.12.2020 | Series A | $55M | Sofinnova ... |
Mentions in press and media 14
| Date | Title | Description |
| 14.04.2025 | Atsena Therapeutics: $150 Million (Series C) Closed To Advance Ocular Gene Therapy Programs | Atsena Therapeutics – a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness – recently announced the closing of an oversubscribed $150 million Series C fnuding.... |
| 04.04.2025 | Atsena Therapeutics Raises $150M in Series C Financing | Atsena Therapeutics, a Durham, NC-based clinical-stage gene therapy company, raised $150M in Series C funding. The round was led by Bain Capital’s Life Sciences team, with participation from an additional new investor, Wellington Management... |
| 02.04.2025 | Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow | Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech’s gene therapy designed to reverse or prevent blindness through a potential market approval. The funding ro... |
| 14.11.2023 | Atsena Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy | - |
| 27.07.2022 | Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle | DURHAM, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the grand opening of... |
| 20.12.2020 | Atsena Therapeutics Raises $55M in Series A Financing | Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing. The round was led by Sofinnova Investments with participation from additional new investors Abingworth and Light... |
| 20.12.2020 | Atsena Therapeutics Raises $55M in Series A Financing | Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing. The round was led by Sofinnova Investments with participation from additional new investors Abingworth and Light... |
| 19.12.2020 | Atsena Therapeutics Raises $55M in Series A Financing | Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing. The round was led by Sofinnova Investments with participation from additional new investors Abingworth and Light... |
| 16.12.2020 | Eyeing phase 3, Atsena raises $55M financing for blindness gene therapy | University of Florida (UF) spinout Atsena Therapeutics has closed a $55 million financing that will help take its gene therapy for a common cause of blindness in children into pivotal trials. Sponsored by Agilent Technologies How would you ... |
| 16.12.2020 | Daily funding roundup - Dec. 16th, 2020 | Truera raised $12M; Curai Health picks up $27.5M: Vercel landed $40M; Bestow secure $70 Hightouch: Hightouch is a Bay Area-based SaaS service that helps businesses sync their customer data across sales and marketing tools. Hightouch has rai... |
Show more